Prescription of insulin glargine in primary care practices in Germany

Experimental and Clinical Endocrinology and Diabetes

Volumn 115, Issue 4, 2007, Pages 252-256

  Rathmann, W ^a   Haastert, B ^a   Riebel, P ^b   Schroeder Bernhardi, D ^b   Kostev, K ^b   Huppertz, E ^c   Giani, G ^a  

^a LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

^b IQVIA   (United States)

^c SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

General practice; Glargine; Insulin therapy; Pharmacoepidemiology

Indexed keywords

ACARBOSE; BIGUANIDE; INSULIN GLARGINE; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DIET; DOSE RESPONSE; FEMALE; GERMANY; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MORBIDITY; OUTCOME ASSESSMENT; PRESCRIPTION; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; AGED; DATABASES, FACTUAL; DIABETES MELLITUS; FEMALE; GERMANY; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PRESCRIPTIONS, DRUG; PRIMARY HEALTH CARE; TREATMENT OUTCOME;

EID: 34248567050     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-972562     Document Type: Article

References (17)

1. Bachmann W, Löbe A, Lacher F. Medikamentös bedingte Hypoglykämien bei Typ-II-Diabetes. Diab Stoffw 1995; 4: 83-89
2. Barnett AH. A review of basal insulins. Diabetic Medicine 2003; 20: 873-885
3. Cohen FJ, Neslusan CA, Conklin JE, Song X. Recent antihyperglycemic prescribing trends for U.S. privately insured patients with type 2 diabetes. Diabetes Care 2003; 26: 1847-1851
4. Dietlein G, Schröder-Bernhardi D. Use of mediplus patient database in healthcare research. Int J Pharmacol Therap 2002; 40: 130-133
5. Dunn CJ, Plosker GL, Keating GM, McKeage K, Scott LJ. Insulin glargine. An updated review of its use in the management of diabetes mellitus. Drugs 2003; 63: 1743-1778
6. Grant RW, Pirraglia PA, Meigs JB, Singer DE. Trends in the complexity of diabetes care in the United States from 1991 to 2000. Arch Intern Med 2004; 164: 1134-1139
7. Hauner H, Köster I, von Ferber L. Prävalenz des Diabetes mellitus in Deutschland 1998-2001. Sekundärdatenanalyse einer Versichertenstichprobe der AOK Hessen/KV Hessen. Dtsch Med Wochenschr 2003; 128: 2632-2638
8. Hauner H. Insulin glargin - das erste lang wirkende Insulinanalogon. Ergebnisse einer Anwendungsbeobachtung mit 10258 Patienten. Deutsches Ärzteblatt 2003; 46: A3022-A3027
9. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Järvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005; 28: 254-259
10. Joost HG, Mengel K. Antidiabetika. In: Schwabe U, Paffrath D (Eds.). Arzneiverordnungs-Report 2002. Springer, Berlin, 2003, pp 170-185
11. Krobot KJ, Miller WC, Kaufman JS, Christensen DB, Preisser JS, Ibrahim MA. Quantifying delay in access to new medical treatment. An application of risk advancement period methodology. Epidemiology 2004; 15: 202-207
12. Larme AC, Pugh JA. Attitudes of primary care providers toward diabetes. Barriers to guideline implementation. Diabetes Care 1998; 21: 1391-1396
13. Meisinger C, Heier M, Doering A, Thorand B, Loewel H, KORA Group. Prevalence of known diabetes and antidiabetic therapy between 1984/1985 and 1999/2001 in southern Germany. Diabetes Care 2004; 27: 2985-2987
14. Rathmann W. Data safety and drug safety in Germany: a closing gap? Pharmacoepidemiology Drug Safety 2001; 10: 625-630
15. Rosenstock J, Schwartz SL, Clark CM, Park GD, Donley DW, Edwards MB. Basal insulin therapy in type 2 diabetes. 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001; 24: 631-636
16. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 35). Lancet 1998; 352: 837-853
17. Wysowski DK, Armstrong G, Governale L. Rapid increase in the use of oral antidiabetic drugs in the United States, 1990-2001. Diabetes Care 2003; 26: 1852-1855